Blood Biomarker May Predict Immunotherapy Outcomes in Lung Cancer

Immunotherapy has transformed the treatment landscape for non-small cell lung cancer (NSCLC), offering long-term survival to patients who once had few options. However, these advanced therapies do not work for everyone, leaving clinicians with the difficult task of predicting who will benefit. Standard tissue biopsies can be invasive, difficult to repeat, and sometimes fail to capture the full complexity of a tumor.

To address this challenge, researchers are focusing on "liquid biopsies"—simple blood tests that can detect circulating molecules shed by tumors and immune cells. A new meta-analysis highlights one such biomarker, known as soluble programmed death-ligand 1 (sPD-L1), which circulates in the blood and may offer a non-invasive window into how a patient will respond to immunotherapy.

The comprehensive analysis of nearly 2,000 patients suggests that baseline levels of sPD-L1 in the bloodstream are strongly linked to survival outcomes. By measuring this biomarker before treatment begins, oncologists may eventually gain a clearer picture of a patient's prognosis and treatment trajectory.

What Happened

A Decade of Data Analyzed

Researchers conducted a systematic review and meta-analysis of clinical studies published between 2015 and 2025. They evaluated the relationship between baseline serum levels of soluble immune checkpoints, specifically sPD-L1, and clinical outcomes in patients undergoing treatment for NSCLC. The final analysis pooled data from 20 distinct studies, representing a total of 1,967 patients.

What The Evidence Shows

Strong Correlation with Survival Outcomes

The pooled analysis revealed a robust correlation between lower baseline levels of sPD-L1 and superior clinical outcomes. Using a random-effects model, the researchers calculated the following key statistics:

For progression-free survival (PFS), patients with lower baseline sPD-L1 had a significantly lower risk of disease progression, with a pooled hazard ratio of 2.26 (95% CI: 1.77-2.87, p < 0.0001).

For overall survival (OS), lower levels were similarly protective, yielding a pooled hazard ratio of 2.04 (95% CI: 1.55-2.68, p < 0.0001).

Conversely, elevated concentrations of sPD-L1 were more frequently observed in male patients, smokers, and individuals with advanced disease characteristics, suggesting that higher levels of the circulating protein may reflect a heavier tumor burden or a more aggressive disease state.

What We Don't Know Yet

Heterogeneity and Lack of Standardized Thresholds

While the findings are highly encouraging, several limitations prevent immediate clinical implementation. The analyzed studies exhibited significant heterogeneity in design, patient characteristics, and the specific immunotherapy agents administered.

Crucially, there is currently no universal, standardized assay or established cutoff threshold to define what constitutes a 'high' versus 'low' level of sPD-L1 in the blood. Different studies used various testing methods, making it difficult to establish a single clinical guideline.

What Comes Next

Standardization and Prospective Trials

Before sPD-L1 testing can be integrated into routine oncology clinics, international research efforts must standardize the laboratory testing methods and establish validated clinical cut-offs. Prospective clinical trials are also needed to confirm whether adjusting treatment strategies based on baseline sPD-L1 levels directly improves patient survival.

What This Means

Moving Toward Personalized Blood-Based Diagnostics

These findings suggest that sPD-L1 has strong potential to serve as a convenient, non-invasive prognostic biomarker. If validated, a simple pre-treatment blood draw could help oncologists stratify patients by risk, offering a valuable complement to traditional tissue-based PD-L1 testing, which can be limited by tumor heterogeneity.

Original Source

PubMed (NCBI E-utilities): https://pubmed.ncbi.nlm.nih.gov/42591702/